Clinical Trials Logo
  1. Home
  2. Chronic Myeloid Leukemia
  3. NCT03882281

Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia — CML  

Chronic Myeloid Leukemia, Chronic Phase Clinical Trial

Official title:
A Randomized, Open, Double-crossing Trial to Evaluate the Effect of Fasting or High-fat Meals on the Pharmacokinetics of Single Oral Administration of HQP1351 Tablets on an Empty Stomach or a High-fat Meal in Patients With Chronic Myeloid Leukemia

Clinical Trial Summary

The purpose of this study is to characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia (CML) in chronic phase (CP) after high-fat and fasting meals separately（Selection of high-fat meal spectrum：《The Food - Effect Bioavailability and Fed Bioequivalence Studies》high fat diet should be 800-1000 kcal heat.).

Clinical Trial Description

The drug being test in this study is HQP1351，the study will characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia（CML）in chronic phase（CP）after high-fat meal and fasting meal separately at a dose of 30mg，single-dose. The study will enroll 12 subjects totally and be randomly divided into 2 groups（A group and B group）. Every group will have 6 subjects. The experiment is divided into two periods，in period 1, subjects in the group A will be given HQP1351 30mg after fasting meal，and the group B will be given HQP1351 30mg after 30 minutes of high-fat meal. Then after a seven-day of cleaning time the two groups of subjects took the drug interchangeably in the period 2. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03882281
Study type Interventional
Source Ascentage Pharma Group Inc.
Contact
Status Completed
Phase Phase 1
Start date March 25, 2019
Completion date November 16, 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04006847 - Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Phase 1/Phase 2
Not yet recruiting NCT06368414 - A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia Phase 2
Active, not recruiting NCT04126681 - A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase Phase 2
Not yet recruiting NCT05543161 - "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"
Recruiting NCT05638763 - Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia Phase 2
Recruiting NCT03610971 - Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Phase 2
Completed NCT03332511 - Efficacy and Safety of Nilotinib in CML-CP Phase 4
Active, not recruiting NCT06233890 - The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
Recruiting NCT03459534 - A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs Phase 3
Completed NCT03885830 - Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
Active, not recruiting NCT04147533 - Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia Phase 2
Recruiting NCT03942094 - Nilotinib for First-line Newly Diagnosed CML-CP Patients Phase 3
Active, not recruiting NCT03933852 - Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose
Recruiting NCT05311943 - Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. Phase 3
Active, not recruiting NCT04160546 - Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) Phase 2
Recruiting NCT04677439 - Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure Phase 4
Active, not recruiting NCT03722420 - Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) Phase 3
Not yet recruiting NCT06163430 - CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia Phase 1
Completed NCT02977312 - Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan N/A
Recruiting NCT06119269 - Ponatinib in CML Patients in Chronic Phase